AlloVir
Julie Ma has extensive work experience in the biotechnology and pharmaceutical industry. Julie currently holds the position of VP, Biometrics at AlloVir since March 2022. Prior to that, they served as VP, Biometrics at Assembly Biosciences, Inc. from August 2020 to March 2022. Julie also spent a significant part of their career at Gilead Sciences, where they held various roles including ED, SD, D, AD in Biostatistics from January 2011 to August 2020. Before joining Gilead Sciences, Julie worked at Amgen as a Senior Manager in Biostatistics from September 2006 to January 2011. Julie began their career at Merck as a Senior Biometrician in Biostatistics from November 2001 to September 2006.
Julie Ma completed their Doctor of Philosophy - PhD in Biostatistics at Columbia University from 1998 to 2001. Julie also holds a Master of Science - MS in Computational Mathematics from the University of Minnesota Duluth, although the dates of their study are not provided.
This person is not in any teams
This person is not in any offices
AlloVir
AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.